Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1

Published 2019 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
Authors
Keywords
Ado-trastuzumab emtansine, Receptor, ErbB-2, Receptor, epidermal growth factor, Drug-related side effects and adverse reactions, Malignant neoplasm of breast, Clinical trial, Phase III
Journal
EUROPEAN JOURNAL OF CANCER
Volume 109, Issue -, Pages 92-102
Publisher
Elsevier BV
Online
2019-01-30
DOI
10.1016/j.ejca.2018.12.022

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.